Pacific Shuanglin Bio-pharmacy Co Ltd

The company maintains a strong liquidity position with a current ratio of 3.3, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its operating cash flow is negative at -215.99 million CNY, and free cash flow is also negative at -27.73 million CNY, suggesting that the company is currently spending more cash than it is generating from operations. The debt-to-equity ratio is 0.1, which is relatively low, indicating that the company is not heavily leveraged. In terms of profitability, the company's return on equity (ROE) is 5.18%, and return on assets (ROA) is 4.43%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, suggesting that the company is not generating returns as efficiently as its peers. The gross profit margin is 41.37%, and the operating margin is 20.00%, which are both in line with the industry average. The company's revenue is primarily concentrated in China, with no significant international exposure disclosed in the available data. The company operates in a single business segment, which is pharmaceuticals, and there is no indication of geographic diversification in the financial snapshot. Looking at the growth trajectory, the company's revenue for the latest period is 2.63 billion CNY. While the financial data does not provide a year-over-year growth rate, the company's price-to-earnings ratio of 25.39 and price-to-book ratio of 1.32 suggest that it is valued at a premium relative to its book value and earnings. The company's capital expenditures are negative at -333.40 million CNY, indicating that it is not investing in new long-term assets at the moment. The company faces a medium liquidity risk due to its negative operating and free cash flows, despite a strong current ratio. The risk assessment also notes that net cash is negative after subtracting total debt, which could pose a challenge in the short term. The dilution risk is assessed as low, and there is no indication of recent share issuance or dilution potential in the data provided. Recent events include a strong analyst price target of 21.43 CNY, which is significantly higher than the current market price of 11.2 CNY. This suggests that analysts have a positive outlook on the company's future performance. The company's ESG score is 33.52, which is below the industry average, with the environment and social pillars scoring 41.69 and 47.27, respectively.